Therapeutic Effect of Zoledronic Acid on Osteoporotic Vertebral Compression Fracture in Elderly Women
ZHONG Jie-lin, CAI Ying, KIM Sung-ho, et al.
Orthopaedics Department Four of Tianjin Teda Hospital, Tianjin (300457), China
Abstract:
Objective To study the effects of zoledronic acid on osteoporosis, bone density and pain in elderly women with osteoporotic vertebral compression fracture. Methods One hundred elderly women with osteoporotic vertebral compression fractures were divided into observation and control groups, n=50. The patients in two groups were treated with percutaneous vertebral plasty. After operation, the patients in observation group were treated with zoledronic acid and those in control group were treated with calcium and vitamin D. The treatment lasted for 12 months, and the changes of visual simulation pain score (VAS), Oswestry functional index (ODI), bone mineral density (BMD), serum 25-hydroxyvitamin D [(25-OH)D], osteocalcin (BGP), bone specific alkaline phosphatase (BALP), nerve growth factor (NGF), prostaglandin E2 (PGE2), neuropeptide Y (NPY) and other indicators were compared before and after treatment. Results There was no statistically significant difference between the two groups before the treatment. After 3 d and 12 months of treatment, the VAS scores of the two groups were significantly lower than those before treatment, and the VAS and ODI scores were significantly lower than those of the control group after 12 months. There was no difference between the contents of BMD, VAS0, BGP, BALP, NGF, PGE2 and NPY of the two groups before treatment:. After 12 months of treatment, the BMD values of lumbar L2-4 and right femoral neck in observation group were (0.685±0.062) and(0.598±0.058) g/cm2, respectively, which were significantly higher than those in the control group [(0.659.048) and (0.568±0.054)g/cm2] (t=2.3916, 62422, P<0.05). The (25-OH) D was (35.41±10.26) ng/mL in observation group, which was significantly higher than that of control group [(28.29±9.13) ng/mL], (t=5.2240, P<0.05). The BGP was (10.15±2.01) ng/mL and the BALP was (16.26±4.05) ng/mL, which were significantly lower than those of the control group [(12.91±3.04) ng/mL and (18.01±3.75) ng/mL] (t=0.1037, 2.1980, P<0.05). The NGF was (261.08±6.51) pg/mL, the PGE2 was (152.57±7.02) ng/mL, and the NPY was(142.03±9.68) ng/mL, which were significantly lower than those of the control group [(277.42±9.74) pg/mL, (169.74±6.52) ng/mL and (156.24±8.95) ng/mL] (t=9.7006, 12.4039, 7.4598, P<0.05). Conclusion Zolephosphonic acid can obviously increase bone density of osteoporotic vertebral fractures in elderly women, improve bone metabolism level, relieve pain, and be used as an effective drug for treating this disease.
